Rodney Young
Director of Finance/CFO chez RAPT THERAPEUTICS, INC.
Fortune : 105 353 $ au 31/03/2024
Profil
Rodney K.
B.
Young is currently the Chief Financial Officer & Secretary at Rapt Therapeutics, Inc. He previously worked as the Chief Financial Officer, VP & Head-IR at StemCells, Inc. from 2005 to 2013, as the Chief Financial Officer at Extropy Pharmaceuticals, Inc. from 2003 to 2005, as the Chief Financial Officer at Cellerant Therapeutics, Inc. from 2015 to 2019, and as the Chief Financial Officer at Aimmune Therapeutics, Inc. from 2014 to 2015.
Young received his undergraduate degree from The University of Chicago and his MBA from The University of Chicago Booth School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RAPT THERAPEUTICS, INC.
0,03% | 28/03/2024 | 11 732 ( 0,03% ) | 105 353 $ | 31/03/2024 |
Postes actifs de Rodney Young
| Sociétés | Poste | Début |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Director of Finance/CFO | 02/12/2019 |
Anciens postes connus de Rodney Young
| Sociétés | Poste | Fin |
|---|---|---|
Cellerant Therapeutics, Inc.
 Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Director of Finance/CFO | 01/11/2019 |
| AIMMUNE THERAPEUTICS, INC. | Director of Finance/CFO | 01/02/2015 |
StemCells, Inc.
 StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Director of Finance/CFO | 01/12/2013 |
| Extropy Pharmaceuticals, Inc. | Director of Finance/CFO | 01/01/2005 |
Formation de Rodney Young
| The University of Chicago | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RAPT THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Health Technology |
Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Health Technology |
| Extropy Pharmaceuticals, Inc. | |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
